{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:15:17Z","timestamp":1792282517802,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T00:00:00Z","timestamp":1223596800000},"content-version":"vor","delay-in-days":2719,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><\/jats:sec><jats:sec><jats:title>Aim and background<\/jats:title><jats:p>Recent data in the literature indicate that antigen\u2010presenting cells (APC) are inactive in tumour tissue because of local immunosuppression. Tumour\u2010infiltrating lymphocyte (TIL) signal activation transducing mechanisms are also seriously impaired. Administration of granulocyte macrophage\u2010colony stimulating factor (GM\u2010CSF) may lead to APC recovery and interleukin (IL)\u20102 may restore local TIL activation. Moreover, IL\u20102 increases the systemic lymphocyte population, an event that seems to correlate with a better prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>The present phase I\u2013II study was carried out to examine whether intralesional injection of GM\u2010CSF followed by subcutaneous IL\u20102 would induce a clinical response in advanced, pretreated elderly melanoma patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixteen patients over 60\u00a0years of age received intralesional GM\u2010CSF (150\u00a0ng per lesion on day 1), generally divided between the two largest cutaneous lesions, followed by perilesional subcutaneous IL\u20102 (3\u00a0000\u00a0000\u00a0IU) for 5\u00a0days (days 3\u20137 inclusive) every 3\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four clinical responses [two partial (PR) and two minimal (MR)] (25%), which also involved lesions that had not been directly treated, and nine cases of stable disease were observed. The response duration for PR and MR was 9, 4, 4 and 2.5+ months, respectively. Stable disease (56%) recorded in the nine patients was short\u2010term (3\u20136\u00a0months). Three patients rapidly progressed after two, two and one therapy cycles, respectively. The patient who reached the best PR had a fairly high absolute lymphocyte count (1600\u20132400\/mm<jats:sup>3<\/jats:sup>). The second one, who reached complete remission after subsequent locoregional chemotherapy and hyperthermia, however, had a low absolute lymphocyte count that had doubled by the end of treatment. Blood lymphocyte values in the other patients were too varied to allow any correlation with clinical response. Therapy was well tolerated and only mild fever was observed, with the exception of one patient who had grade 3 fever, with muscle pain and arthralgia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Considering the very low toxicity observed, this treatment might be indicated in elderly patients for whom systemic therapy is no longer a viable option. Improved scheduling and timing could result from further studies.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1468-3083.2001.00254.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:21:58Z","timestamp":1027678918000},"page":"218-223","source":"Crossref","is-referenced-by-count":38,"title":["Intralesional granulocyte\u2010monocyte colony\u2010stimulating factor followed by subcutaneous interleukin\u20102 in metastatic melanoma: a pilot study in elderly patients"],"prefix":"10.1111","volume":"15","author":[{"given":"L","family":"Ridolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ascari\u2010Raccagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MG","family":"Righini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(91)90099-M"},{"key":"e_1_2_6_3_2","first-page":"155","article-title":"Production of cytokines by human melanoma cells and melanocytes. Recent results","volume":"139","author":"Kruger\u2010Krasagakes\u2010 S","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910550118"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199506000-00006"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630210"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.4049\/jimmunol.154.7.3383","article-title":"Potential involvement of IL\u201010 in suppressing tumor\u2010associated macrophages. Colon\u201026\u2010derived prostaglandin E2 inhibits TNF\u2010alpha release via a mechanism involving IL\u201010","volume":"154","author":"Kambayashi T","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_6_8_2","first-page":"1178","article-title":"Induction of antigen\u2010specific T cell anergy: an early event in the course of tumor progression","volume":"95","author":"Staveley\u2010O'Carrol K","year":"1998","journal-title":"Immunology"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1996.0139"},{"issue":"2","key":"e_1_2_6_10_2","first-page":"641","article-title":"Human sunlight\u2010induced basal\u2010cell\u2010carcinoma\u2010associated dendritic cells are deficient in T cell co\u2010stimulatory molecules and are impaired as antigen\u2010 presenting cells","volume":"150","author":"Nestle FO","year":"1997","journal-title":"Am J Pathol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01030-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/360258a0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199404000-00008"},{"key":"e_1_2_6_15_2","first-page":"1653a","article-title":"In\u2010vivo generation of dendritic cells (DC) by the combination of interleukin\u20104 (IL\u20104) and granulocyte\u2010macrophage colony stimulating factor (GM\u2010CSF) in patients (PTS) with metastatic cancer \u2013 a phase I trial","volume":"17","author":"Gitlitz B","year":"1998","journal-title":"Proc ASCO"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3245"},{"key":"e_1_2_6_17_2","first-page":"1","article-title":"Dendritic cells for immunotherapy","volume":"11","author":"Herbst B","year":"1998","journal-title":"Biomed Prog"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050317"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050349"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199606000-00008"},{"key":"e_1_2_6_21_2","first-page":"1651a","article-title":"Intradermal (ID) injection of granulocyte\u2010macrophage stimulating factor (GM\u2010CSF) in patients (PTS) with metastatic melanoma","volume":"17","author":"Nasi ML","year":"1998","journal-title":"Proc ASCO"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346030-00009"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(94)90004-3"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1994.tb04156.x"},{"key":"e_1_2_6_25_2","first-page":"1263","article-title":"Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy","volume":"2","author":"Rabinowich H","year":"1996","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_26_2","first-page":"2191a","article-title":"Tzeta and epsilon chains and p56lck restoral in TIL before therapeutic reinfusion in 39 patients","volume":"17","author":"Ridolfi R","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1296-1361"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050447"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01517175"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000217850"},{"key":"e_1_2_6_32_2","first-page":"25","article-title":"Prognostic factors for survival in patients with inoperable lung cancer","volume":"65","author":"Stanley KE.","year":"1980","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00265-5"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01036-0"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-3083.2001.00254.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-3083.2001.00254.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-3083.2001.00254.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T10:33:48Z","timestamp":1697625228000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1468-3083.2001.00254.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1046\/j.1468-3083.2001.00254.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1468-3083.2001.00254.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}